CYP51 Mutations in the Fusarium solani Species Complex: First Clue to Understand the Low Susceptibility to Azoles of the Genus Fusarium
by
,
Pierre Vermeulen
1,2, 
Arnaud Gruez
3,
Anne-Lyse Babin
1,
Jean-Pol Frippiat
1,
Marie Machouart
1,2 and
Anne Debourgogne
1,2,* 1
Laboratoire Stress Immunité Pathogènes, UR 7300, Faculté de Médecine, Université de Lorraine, 9 Avenue de la Forêt de Haye, F-54500 Vandœuvre-lès-Nancy, France
2
Service de Microbiologie, CHRU de Nancy, Hôpitaux de Brabois, 11 Allée du Morvan, F-54511 Vandœuvre-lès-Nancy, France
3
IMoPA, CNRS, Université de Lorraine, F-54000 Nancy, France
*
Author to whom correspondence should be addressed.
J. Fungi 2022, 8(5), 533; https://doi.org/10.3390/jof8050533
Submission received: 25 April 2022
/
Revised: 12 May 2022
/
Accepted: 18 May 2022
/
Published: 20 May 2022
(This article belongs to the Special Issue Clinically Relevant Fusarium Species)
Abstract
:Members of Fusarium solani species complex (FSSC) are cosmopolitan filamentous fungi responsible for invasive fungal infections in immunocompromised patients. Despite the treatment recommendations, many strains show reduced sensitivity to voriconazole. The objective of this work was to investigate the potential relationship between azole susceptibility and mutations in CYP51 protein sequences. Minimal inhibitory concentrations (MICs) for azole antifungals have been determined using the CLSI (Clinical and Laboratory Standards Institute) microdilution method on a panel of clinical and environmental strains. CYP51A, CYP51B and CYP51C genes for each strain have been sequenced using the Sanger method. Amino acid substitutions described in multiple azole-resistant Aspergillus fumigatus (mtrAf) strains have been sought and compared with other Fusarium complexes’ strains. Our results show that FSSC exhibit point mutations similar to those described in mtrAf. Protein sequence alignments of CYP51A, CYP51B and CYP51C have highlighted different profiles based on sequence similarity. A link between voriconazole MICs and protein sequences was observed, suggesting that these mutations could be an explanation for the intrinsic azole resistance in the genus Fusarium. Thus, this innovative approach provided clues to understand low azole susceptibility in FSSC and may contribute to improving the treatment of FSSC infection.
1. Introduction
The genus Fusarium spp., mainly known as a plant pathogen, is cosmopolite and present in soil, water, and air. Fusarium is classified in different species complexes, and some of them have been described as human pathogens, such as Fusarium solani species complex (FSSC), Fusarium oxysporum species complex (FOSC), or Fusarium fujikuroi species complex (FFSC). Among them, the Fusarium solani species complex is the most represented [1,2]. Actually, the nomenclature of this complex is under revisions. Indeed, taxonomy experts propose to reclassify FSSC in a new genus, Neocosmospora. In contrast, the opposite view reasserts that FSSC has to be included in the genus Fusarium, being the most practical scientific option [3,4]. Fusarium can cause skin and ocular infections [5], but can also lead to severe invasive fungal infections, fusariosis, in immunodeficient patients, in particular those who have received stem cells transplants or suffer from acute leukemia [1,6,7]. The number of fusariosis cases has been steadily increasing over the last two decades [8,9].
Therapeutic drugs for fusariosis treatment are limited. Indeed, Fusarium spp. presents a low susceptibility to most antifungals. Due to the lack of clinical trials, the optimal treatment strategy for patients with fusariosis remains unclear. However, the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the European Confederation of Medical Mycology (ECMM) published joint guidelines for the management of fusariosis and recommended the use of voriconazole, associated or not with amphotericin B [10,11]. Despite these recommendations, many studies have demonstrated a high variability of voriconazole MIC between Fusarium strains. In their article, Debourgogne et al. determined voriconazole MICs for 48 FSSCs from clinical and environmental samples by the CLSI M38-A2 method. They found a mean MIC of 4.6 µg/mL and a MIC90 of 8 µg/mL [12].
Voriconazole belongs to the class of azole antifungals, whose mechanism of action is based on the inhibition of ergosterol synthesis. Ergosterol is a major component of the fungal membrane. Its production is managed by the 14α-demethylase enzyme, the target of azole antifungals [13,14]. The binding of azole to the ferric iron moiety of the heme-binding site blocks the enzyme’s natural substrate lanosterol, disrupting the biosynthetic pathway [15]. In the Fusarium genus, this enzyme is encoded by the CYP51 gene and is present in three isoforms: A, B, and C [16].
In fungi, azole resistance involves multiple mechanisms, such as (i) target alteration or overexpression, (ii) upregulation of multidrug transporters (efflux and impermeability), or (iii) cellular stress responses [17,18,19].
Qualitative modifications such as amino acid substitutions within the target inhibiting drug binding are a widespread azole-resistance mechanism in fungi. Protein overexpression is also a frequent mechanism among azole-resistant clinical isolates of yeasts, such as C. albicans with ERG11 [19]. In filamentous fungi, the mechanism or the contribution of overexpression to azole resistance remains unclear [20]. Two cases of CYP51A overexpression in A. fumigatus have been described [21]. Another ubiquitous resistance mechanism involves membrane-associated efflux pumps. Two systems have been highlighted, the ATP-binding cassette (ABC) superfamily which use ATP hydrolysis, and the major facilitator superfamily (MFS) using the electrochemical proton-motive force to power drug efflux.
In A. fumigatus, target alteration inducing azole resistance can emerge in response to azole therapy [22]. The most commonly reported resistance mechanisms with CYP51A are substitutions at codons 54 and 220 [23]. However, resistance could also be of environmental origin and driven by the agricultural use of azoles. The first resistance mechanism described from environmental origin consists of a combination of a substitution at codon 98 in the CYP51A gene and a 34 base-pair tandem repeat (TR) in the gene promoter (TR34/L98H) [24].
The objective of this study was to identify a potential relationship between azole susceptibility and modification by target mutations in Fusarium solani species complex to better understand resistance mechanisms and help adapt treatment of this multi-resistant pathogen.
2. Materials and Methods
2.1. Isolates
Seventeen FSSC isolates presenting different genotypes were used for this study [25]. Their CBS-KNAW Fungal Biodiversity Center collection numbers and characteristics are listed in Table 1. Fusarium strains were grown on Sabouraud broth (Sigma-Aldrich, St. Louis, MO, USA) agar medium and incubated at 30 °C. Strains were stored at −20 °C in water/glycerol (1/1).
2.2. Antifungal Susceptibility Testing
Minimal inhibitory concentration (MIC) determination by microdilution testing was performed following the CLSI M38-A2 reference method [26]. Fusarium falciforme (ATCC MYA-3636) was used as a quality control strain and was compliant for the study. Antifungals used in the study were voriconazole (VRZ) (range 0.03–16 µg/mL), itraconazole (ITZ) (range 0.03–16 µg/mL), posaconazole (PSZ) (range 0.03–16 µg/mL), and isavuconazole (IVZ) (range 0.03–16 µg/mL) (Sigma-Aldrich, St. Louis, MO, USA). MIC is the antifungal concentration that led to a complete inhibition of visual growth after 48 h of incubation at 37 °C. Each strain was tested in triplicate (biological replicate), and for each MIC determination, FSSC strains were tested in duplicate (technical replicate).
2.3. Genomic DNA Extraction
DNA was extracted from agar cultures using the Monarch Genomic DNA Purification Kit (New England Biolabs® Inc., Ipswich, MA, USA) according to the manufacturer’s instructions. The DNA concentration was determined using a Nanodrop 2000 system (Thermo Scientific, Waltham, MA, USA).
2.4. Amplification and Sequencing of CYP51A, CYP51B, and CYP51C Genes
The CYP51A, CYP51B, and CYP51C genes were amplified using previously described primers [27]. The reaction mixtures contained 0.2 µM of each primer, 25 µL of Taq’Ozyme Purple Mix 2 (Ozyme, Saint-Cyr-l’École, France), and 5 µL of gDNA in a final volume of 50 µL. Samples were amplified using a CFX96 Real-Time PCR System (BioRad, Marnes-la-Coquette, France) and the following cycling protocol: one initial cycle of 2 min at 95 °C, followed by 35 cycles of 30 s at 95 °C, 30 s at 55 °C, and 2 min at 72 °C, with one final cycle of 5 min at 72 °C. PCR quality was assessed by 1.5% agarose gel electrophoresis (120 V, 20 min) and visualization using the Fusion Fx7 device (Vilber Lourmat, Eberhardzell, Germany). PCR product sequencing was performed using the Sanger method by Eurofins Genomics (Ebersberg, Germany) with the same primers.
2.5. Bioinformatic Analysis
Sequences and alignments have been interpreted using the Geneious Prime® software (Geneious v2021.1.1 created by Biomatters, accessed in May 2021, available from https://www.geneious.com) and compared with a database using NCBI BLAST [28]. Nucleotide sequences were confirmed thanks to described sequences from Fusarium vanettenii mpVI 77-13-4 (accession numbers in Table 2). For each strain, mRNA sequences were obtained by sequence alignment with CYP51A, CYP51B, and CYP51C mRNAs of Fusarium vanettenii mpVI 77-13-4 (accession numbers in Table 2). Translation and protein sequence alignments were performed using Geneious Prime® software. In this study, different protein profiles were identified, and two proteins were considered to belong to the same profile when the percentage of similarity was ≥99%.
2.6. Comparison of CYP Proteins’ Mutations
The positions of mutations in CYP51A and CYP51B were compared to those associated with azole resistance in Aspergillus fumigatus NRRL:163 (WT reference strain) [23]. Unfortunately, A. fumigatus does not possess a third CYP51 isoform. However, CYP51C has been characterized in Aspergillus flavus NRRL3357 (WT reference strain) and mutations associated with azole resistance have been described despite controversial data in the literature. Liu et al. showed that a T788G mutation in the CYP51C gene was responsible for voriconazole resistance in A. flavus. However, Paul et al. contradicted this conclusion because this mutation was not found in their strains and another mutation (Y319H) has been highlighted and implicated in mediating voriconazole resistance [29,30,31]. CYP51A protein sequences from our panel of FSSC strains have been compared to other complexes in the genus Fusarium. Reference strains from environmental and clinical Fusarium complex species known to be pathogenic in humans or plants have been selected (Table 3). This comparison was carried out to highlight shared point mutations that could explain voriconazole susceptibility variability at the complex or genus levels.
2.7. Protein Modeling
The three-dimensional (3D) homology structure of FSSC CYP51A protein was modeled by using the I-TASSER server (http://zhanglab.ccmb.med.umich.edu/I-TASSER (accessed in October 2021)) [32,33], using Fusarium vanettenii mpVI 77-13-4 as a query sequence. The crystal structure of lanosterol 14-alpha demethylase (PDB ID 5eqb), sharing a sequence identity of 45.1% and a TM-score of 0.984 (coverage of 99%), was used as the template for model building. The CYP51A model was studied and figures were prepared using the PyMOL Molecular Graphics System, v2.5.2 (Schrödinger, LLC, New York, NY, USA).
3. Results
3.1. Antifungal Susceptibility Testing
Voriconazole was the antifungal agent with high MIC variabilities between strains. Its MIC median and ranges were, respectively, 8 and 2–16 µg/mL. Eight strains among seventeen (47%) had a VRZ MIC value of 8 µg/mL. All strains presented high MICs for itraconazole and posaconazole, with values higher than 16 µg/mL, except FSSC20 which presented a MIC of posaconazole of 8 µg/mL. Determining the exact MIC value over 16 µg/mL for ITZ and PSZ was not possible due to the lack of solubility of the azole agents. Like voriconazole, isavuconazole presented variability of susceptibility. Its MIC median was 16 µg/mL (range 4–64 µg/mL) (Table 4). MICs for the quality control strain were in the expected range for each experiment.
3.2. Protein Profiles and Minimal Inhibitory Concentration
Protein sequence analysis of the 17 FSSC strains revealed 54, 23, and 29 mutations for CYP51A, B, and C, respectively. The comparison of protein sequences highlighted 9 profiles for CYP51A (1a to 9a), 4 profiles for CYP51B (1b to 4b), and 5 profiles for CYP51C (1c to 5c) (Table 5). The distribution of the different FSSC strains according to their voriconazole MICs revealed a link between MIC and protein sequence. Indeed, strains with low voriconazole MICs shared the same profile, except for FSSC20 and FSSC99, which presented a different VRZ MIC from one dilution.
3.3. Comparison with Aspergillus fumigatus CYP51A
Only 5 of the 23 mutations (22, 172, 220, 255, and 427) described in A. fumigatus as being associated with azole resistance were found in our FSSC strains (Table 6). Mutations at positions 22, 220, 255, and 427 in FSSC strains were different than those of A. fumigatus wild-type (Af WT) and mutations observed at these positions in A. fumigatus resistant to azoles (Af R). On the contrary, the mutation at position 172 was different from Af WT but identical to Af R. All FSSC strains shared these mutations, inducing the same amino acid changes.
3.4. Modeling Structure of FSSC CYP51A Protein
The five mutations shared by all FSSC strains and involved in azole resistance of A. fumigatus have been highlighted in the model of CYP51A in order to assess their impact on 14α-demethylase (Figure 1). The amino acids at positions 22, 170, 253, and 422 are not located near the active site nor near the substrate channel, but at the protein surface. The side chain of H22 interacts with a crevice formed by residues W41, L42, and P43 that are located in the loop before the short αA′ helix according to CYP nomenclature. This helix participates at the channel entry of the substrate. As a consequence, the mutation at position 22 can influence the positioning of the αA′ helix and reshape the surface of the channel entry. This modification could induce azole discrimination or forbid the accessibility of the azole to the active site by steric hindrance, depending on the interaction that could block the entry of the active site against the membrane. Concerning the point mutations at positions 170, 253, and 422, they are located in the β31, αG-αH, and αK′-αL loops, respectively. How these three substitutions might impact azole binding is unknown and will require further study. Amino acid L218 interacts with amino acid F75, and both of them are located at the entry of the substrate channel of CYP51A, in close proximity to the modeled itraconazole. As a consequence, position 218 might be implicated in the interaction between the enzyme and its substrates. Physicochemical properties of the amino acids observed in the five mutations of interest (position 22, 170, 218, 253, and 422 in FSSC strains) have been compared with those described in A. fumigatus (Table 7). As described in the literature, mutations of CYP51A M220 to I, K, T, or V residues were associated with azole resistance in A. fumigatus. Interestingly, in FSSC strains, the amino acid at the equivalent position is a leucine (L218). This residue is structurally very close to isoleucine, which is present in all FSSC strains.
3.5. Comparison of Aspergillus fumigatus CYP51B and Aspergillus flavus CYP51C
The same process has been applied for CYP51B. None of the four mutations described in A. fumigatus have been observed in the panel of studied FSSC strains. At these positions, FSSC strains share the same amino acid as the one described in the WT A. fumigatus reference strain.
Only two mutations in CYP51C have been described and associated with Aspergillus flavus resistance to azoles. At position 240 (249 for FSSC), all FSSC strains present a different amino acid (G) than A. flavus WT (S) and azole resistant (A). Concerning the second mutation, FSSC strains share the same amino acid as the one described in the WT A. flavus reference strain
3.6. Comparison of FSSC vs. Other Fusarium Species Complex
We have demonstrated that all studied FSSC strains share the same amino acid mutations known to be associated with azole resistance in A. fumigatus. We focused on the five mutations in CYP51A sequences described previously (H22, V170, L218, G253, D422) and compared them with other FSSC genotypes as well as different species complexes previously described in the literature (Fusarium oxysporum species complex (FOSC), Fusarium fujikuroi species complex (FFSC), and Fusarium sambucinum species complex (FSAMSC)) (Table 8). Other genotypes belonging to FSSC present the same amino acids as our panel. Interestingly, FSAMSC differs from our panel, with only two common amino acids among the five point mutations. The H22 mutation seems to be specific to FSSC as only FSSC strains share this mutation, which is substituted by an asparagine (N) in the other species complexes. Concerning position 218 located at the channel entry, all the strains from the different complexes present the same amino acid (leucine (L)).
4. Discussion
MIC determination in our panel of FSSC strains showed a low susceptibility for azoles used in clinical practice and a high variability of susceptibility for voriconazole and isavuconazole (MIC values ranged from 2 to 16 and 4 to 64 µg/mL, respectively). Our MIC values were close to the range of 1–16 µg/mL formerly defined for Fusarium solani complex species [1,35,36]. Our results also revealed that all FSSC strains exhibited itraconazole and posaconazole MICs superior to 16 µg/mL, except for the FSSC20 strain which had a MICPSZ of 8 µg/mL. This observation has also been reported in other publications [10,35]. Tortorano et al. showed comparable results for posaconazole as the majority of their FSSC strains presented MICs of 16 µg/mL, except for one strain for which it was 1 µg/mL [11]. Concerning isavuconazole, the results showed a larger range of MIC values, from 4 to 64 µg/mL. Most of its activities against Fusarium spp. have shown MIC values often greater than 16 or even 32 µg/mL [10,37,38,39]. Our findings support the high MIC values previously reported and revealed that 64% of FSSC strains exhibited MICs superior or equal to 16 µg/mL.
The variability of susceptibility to voriconazole observed for FSSC strains in our study raises the question of the mechanism responsible for this low susceptibility. Alignments of CYP51A, CYP51B, and CYP51C protein sequences highlighted similarities between strains, but also allowed their classification into different profiles: 9, 4, and 5 profiles for CYP51A, CYP51B, and CYP51C, respectively. To the best of our knowledge, this approach has not been carried out before. Furthermore, sequence profiling allowed to link voriconazole MICs with the CYP51 protein sequence.
Up to now, no mutations involved in azole resistance within the 14α-demethylase gene of the Fusarium solani species complex had been described. By comparing with CYP51A of Aspergillus fumigatus, we showed that 5 of the 23 mutations described in the literature as being associated with a change in azole sensitivity in this pathogen were found in all tested FSSC strains. Most of these mutations have been described as responsible for voriconazole resistance in A. fumigatus [23]. In this fungus, a substitution of methionine 220 to lysine, isoleucine, valine, or threonine impacts voriconazole susceptibility. Indeed, it has been shown that clinical strains exhibiting the M220I mutation present increased voriconazole MICs [40]. This fact has also been proven using yeast clones expressing the CYP51 M220I mutant of A. fumigatus [41]. Isoleucine found in A. fumigatus is very structurally close to leucine found at position 218 in our panel of FSSCs. They are both apolar amino acids and share the same physicochemical properties. It has been shown that changes in amino acids due to their physicochemical properties (polarity, hydrophobicity, etc.) are responsible for modifying protein conformation and consequently, its affinity with targets such as azoles [42]. Interestingly, L218, corresponding to M220 for A. fumigatus, is common to all strains. By structure modeling of CYP51A, with Fusarium vanettenii mpVI 77-13-4 as a query sequence, we observed that L218 is located at the channel entry of the substrate. This conserved leucine at position 218 and its role in protein channel conformation were also described by James et al. [27]. Thus, we propose that the L218 residue is directly involved in the discrimination of azole by modifying the shape of the channel entry of the substrate for the Fusarium solani species complex or associated with the genus Fusarium. Concerning the influence of the mutation at the position 22 on azole discrimination, one possibility could involve its influence on the orientation of the αA′ helix that constitutes an integral part of the channel entry, while the second possibility could be the locking of CYP51A against the membrane, that could infer with the accessibility of the long azole chain to the active site. Mutations at positions 170, 253, and 422 also led to a low susceptibility for azole in our study, whereas they are located far from the azole binding site. Albeit their precise role in azole discrimination is difficult to assess at the molecular level, one can hypothesize that amino acids at these positions could be key residues that affect the plasticity of CYP51A within Fusarium solani species complex, which is required for ligand binding.
The literature reports that some strains of A. fumigatus show resistance or reduced sensitivity to one or more azoles without any mutations detected in the CYP51A gene. These phenotypes have been explained by the presence of mutations in the CYP51B gene [43,44]. These point mutations were not found in our panel. The same observation was made for CYP51C in comparison with Aspergillus flavus.
Few studies have focused on Fusarium species complexes other than FSSC and their resistance to clinically used azoles. Indeed, the genus Fusarium is also a plant pathogen. Studies about Fusarium graminearum (FSAMSC) and FOSC have shown that the CYP51A gene encodes an inducible 14α-demethylase, determining sensitivity to azoles. On the contrary, CYP51B is a 14α-demethylase involved in the formation of ascospores, but is barely impacted by antifungals. Indeed, an increase in sensitivity to azole antifungals has been described in strains deleted in CYP51A (ΔCYP51A), but no difference was observed for ΔCYP51B mutants. CYP51C is genus-specific and is found in the genus Fusarium. However, its role is not clearly established. Studies show that CYP51C is not involved in sterol 14-demethylation, but gene deletion increases in sensitivity for some sterol demethylase inhibitors [45,46]. Recently, novel CYP51 paralogues have been described. Similar to CYP51B, a new paralogue named CYP51D is involved in azole resistance and occurs in genomes of fungi belonging to Eurotiomycetes. A novel partial CYP51A gene encodes a truncated form of CYP51A responsible for azole resistance [47]. Therefore, we focused on CYP51A, the protein most responsible of azole resistance in the genus Fusarium [20,45,48,49,50]. To further characterize our findings about amino acid changes, we compared the CYP51A protein sequence of our FSSC strains with other strains from the same complex and with strains from different complexes. All strains from the different complexes presented the same amino acid at position 218 (L218) as that in our panel. Our hypothesis is that this observation could be a first clue to explain the low susceptibility of clinically used azole drugs in the genus Fusarium. More studies should be performed to confirm and generalize our findings in fusarioid fungi.
Author Contributions
Conceptualization, P.V. and A.D.; methodology, P.V., A.G. and A.D.; software, P.V. and A.G.; validation, P.V., A.G. and A.D.; formal analysis, P.V.; resources, A.-L.B.; writing—original draft preparation, P.V.; writing—review and editing, A.D., A.G., M.M. and J.-P.F.; supervision, A.D.; project administration, J.-P.F. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Not applicable.
Data Availability Statement
Not applicable.
Acknowledgments
This work was presented in part at the Congress of the French Society of Medical Mycology, Lyon, France, 2021. We acknowledge the French Ministry of Higher Education and Research and the Université de Lorraine for their support.
Conflicts of Interest
The authors declare no conflict of interest.
References
- Nucci, M.; Anaissie, E. Fusarium Infections in Immunocompromised Patients. Clin. Microbiol. Rev. 2007, 20, 695–704. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Guarro, J. Fusariosis, a Complex Infection Caused by a High Diversity of Fungal Species Refractory to Treatment. Eur. J. Clin. Microbiol. Infect. Dis. 2013, 32, 1491–1500. [Google Scholar] [CrossRef] [PubMed]
- Geiser, D.M.; Al-Hatmi, A.M.S.; Aoki, T.; Arie, T.; Balmas, V.; Barnes, I.; Bergstrom, G.C.; Bhattacharyya, M.K.; Blomquist, C.L.; Bowden, R.L.; et al. Phylogenomic Analysis of a 55.1-Kb 19-Gene Dataset Resolves a Monophyletic Fusarium That Includes the Fusarium Solani Species Complex. Phytopathology 2021, 111, 1064–1079. [Google Scholar] [CrossRef] [PubMed]
- Crous, P.W.; Lombard, L.; Sandoval-Denis, M.; Seifert, K.A.; Schroers, H.-J.; Chaverri, P.; Gené, J.; Guarro, J.; Hirooka, Y.; Bensch, K.; et al. Fusarium: More than a Node or a Foot-Shaped Basal Cell. Stud. Mycol. 2021, 98, 100116. [Google Scholar] [CrossRef]
- Zhang, N.; O’Donnell, K.; Sutton, D.A.; Nalim, F.A.; Summerbell, R.C.; Padhye, A.A.; Geiser, D.M. Members of the Fusarium Solani Species Complex That Cause Infections in Both Humans and Plants Are Common in the Environment. J. Clin. Microbiol. 2006, 44, 2186–2190. [Google Scholar] [CrossRef] [Green Version]
- Krcmery, V.; Jesenska, Z.; Spanik, S.; Gyarfas, J.; Nogova, J.; Botek, R.; Mardiak, J.; Sufliarsky, J.; Sisolakova, J.; Vanickova, M.; et al. Fungaemia Due to Fusarium spp. in Cancer Patients. J. Hosp. Infect. 1997, 36, 223–228. [Google Scholar] [CrossRef]
- Nucci, M.; Anaissie, E.J.; Queiroz-Telles, F.; Martins, C.A.; Trabasso, P.; Solza, C.; Mangini, C.; Simões, B.P.; Colombo, A.L.; Vaz, J.; et al. Outcome Predictors of 84 Patients with Hematologic Malignancies and Fusarium Infection. Cancer 2003, 98, 315–319. [Google Scholar] [CrossRef]
- Nucci, M.; Varon, A.G.; Garnica, M.; Akiti, T.; Barreiros, G.; Trope, B.M.; Nouér, S.A. Increased Incidence of Invasive Fusariosis with Cutaneous Portal of Entry, Brazil. Emerg. Infect. Dis. 2013, 19, 1567–1572. [Google Scholar] [CrossRef]
- Marr, K.A.; Carter, R.A.; Crippa, F.; Wald, A.; Corey, L. Epidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant Recipients. Clin. Infect. Dis. 2002, 34, 909–917. [Google Scholar] [CrossRef] [Green Version]
- Herkert, P.F.; Al-Hatmi, A.M.S.; de Oliveira Salvador, G.L.; Muro, M.D.; Pinheiro, R.L.; Nucci, M.; Queiroz-Telles, F.; de Hoog, G.S.; Meis, J.F. Molecular Characterization and Antifungal Susceptibility of Clinical Fusarium Species from Brazil. Front. Microbiol. 2019, 10, 737. [Google Scholar] [CrossRef] [Green Version]
- Tortorano, A.M.; Prigitano, A.; Esposto, M.C.; Arsic Arsenijevic, V.; Kolarovic, J.; Ivanovic, D.; Paripovic, L.; Klingspor, L.; Nordøy, I.; Hamal, P.; et al. European Confederation of Medical Mycology (ECMM) Epidemiological Survey on Invasive Infections Due to Fusarium Species in Europe. Eur. J. Clin. Microbiol. Infect. Dis. 2014, 33, 1623–1630. [Google Scholar] [CrossRef] [PubMed]
- Debourgogne, A.; de Hoog, S.; Lozniewski, A.; Machouart, M. Amphotericin B and Voriconazole Susceptibility Profiles for the Fusarium Solani Species Complex: Comparison between the E-Test and CLSI M38-A2 Microdilution Methodology. Eur. J. Clin. Microbiol. Infect. Dis. 2012, 31, 615–618. [Google Scholar] [CrossRef] [PubMed]
- Lamb, D.; Kelly, D.; Kelly, S. Molecular Aspects of Azole Antifungal Action and Resistance. Drug Resist. Updat. 1999, 2, 390–402. [Google Scholar] [CrossRef] [PubMed]
- Hu, Z.; He, B.; Ma, L.; Sun, Y.; Niu, Y.; Zeng, B. Recent Advances in Ergosterol Biosynthesis and Regulation Mechanisms in Saccharomyces Cerevisiae. Indian J. Microbiol. 2017, 57, 270–277. [Google Scholar] [CrossRef]
- Odds, F.C.; Brown, A.J.P.; Gow, N.A.R. Antifungal Agents: Mechanisms of Action. Trends Microbiol. 2003, 11, 272–279. [Google Scholar] [CrossRef]
- Becher, R.; Weihmann, F.; Deising, H.B.; Wirsel, S.G. Development of a Novel Multiplex DNA Microarray for Fusarium Graminearum and Analysis of Azole Fungicide Responses. BMC Genomics 2011, 12, 52. [Google Scholar] [CrossRef] [Green Version]
- Ghannoum, M.A.; Rice, L.B. Antifungal Agents: Mode of Action, Mechanisms of Resistance, and Correlation of These Mechanisms with Bacterial Resistance. Clin. Microbiol. Rev. 1999, 12, 501–517. [Google Scholar] [CrossRef] [Green Version]
- Wiederhold, N.P. Antifungal Resistance: Current Trends and Future Strategies to Combat. Infect. Drug Resist. 2017, 10, 249–259. [Google Scholar] [CrossRef] [Green Version]
- Cowen, L.E.; Sanglard, D.; Howard, S.J.; Rogers, P.D.; Perlin, D.S. Mechanisms of Antifungal Drug Resistance. Cold Spring Harb. Perspect. Med. 2015, 5, a019752. [Google Scholar] [CrossRef]
- D’Agostino, M.; Lemmet, T.; Dufay, C.; Luc, A.; Frippiat, J.P.; Machouart, M.; Debourgogne, A. Overinduction of CYP51A Gene After Exposure to Azole Antifungals Provides a First Clue to Resistance Mechanism in Fusarium Solani Species Complex. Microb. Drug Resist. Larchmt. N 2018, 24, 768–773. [Google Scholar] [CrossRef]
- Arendrup, M.C.; Mavridou, E.; Mortensen, K.L.; Snelders, E.; Frimodt-Møller, N.; Khan, H.; Melchers, W.J.G.; Verweij, P.E. Development of Azole Resistance in Aspergillus Fumigatus during Azole Therapy Associated with Change in Virulence. PLoS ONE 2010, 5, e10080. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Snelders, E.; Camps, S.M.T.; Karawajczyk, A.; Schaftenaar, G.; Kema, G.H.J.; van der Lee, H.A.; Klaassen, C.H.; Melchers, W.J.G.; Verweij, P.E. Triazole Fungicides Can Induce Cross-Resistance to Medical Triazoles in Aspergillus Fumigatus. PLoS ONE 2012, 7, e31801. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Howard, S.J.; Arendrup, M.C. Acquired Antifungal Drug Resistance in Aspergillus Fumigatus: Epidemiology and Detection. Med. Mycol. 2011, 49, S90–S95. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mellado, E.; Garcia-Effron, G.; Alcázar-Fuoli, L.; Melchers, W.J.G.; Verweij, P.E.; Cuenca-Estrella, M.; Rodríguez-Tudela, J.L. A New Aspergillus Fumigatus Resistance Mechanism Conferring In Vitro Cross-Resistance to Azole Antifungals Involves a Combination of Cyp51A Alterations. Antimicrob. Agents Chemother. 2007, 51, 1897–1904. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Debourgogne, A.; Gueidan, C.; de Hoog, S.; Lozniewski, A.; Machouart, M. Comparison of Two DNA Sequence-Based Typing Schemes for the Fusarium Solani Species Complex and Proposal of a New Consensus Method. J. Microbiol. Methods 2012, 91, 65–72. [Google Scholar] [CrossRef]
- Alexander, B.D.; Procop, G.W.; Dufresne, P.; Espinel-Ingroff, A.; Fuller, J.; Ghannoum, M.A.; Hanson, K.E.; Holliday, D.; Hollida, N.M.; Ostrosky-Zeichner, L.; et al. Clinical and Laboratory Standards Institute. In Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2017. [Google Scholar]
- James, J.E.; Lamping, E.; Santhanam, J.; Milne, T.J.; Abd Razak, M.F.; Zakaria, L.; Cannon, R.D. A 23 Bp Cyp51A Promoter Deletion Associated with Voriconazole Resistance in Clinical and Environmental Isolates of Neocosmospora Keratoplastica. Front. Microbiol. 2020, 11, 272. [Google Scholar] [CrossRef]
- Altschul, S.F.; Gish, W.; Miller, W.; Myers, E.W.; Lipman, D.J. Basic Local Alignment Search Tool. J. Mol. Biol. 1990, 215, 403–410. [Google Scholar] [CrossRef]
- Liu, W.; Sun, Y.; Chen, W.; Liu, W.; Wan, Z.; Bu, D.; Li, R. The T788G Mutation in the Cyp51C Gene Confers Voriconazole Resistance in Aspergillus Flavus Causing Aspergillosis. Antimicrob. Agents Chemother. 2012, 56, 2598–2603. [Google Scholar] [CrossRef] [Green Version]
- Lucio, J.; Gonzalez-Jimenez, I.; Rivero-Menendez, O.; Alastruey-Izquierdo, A.; Pelaez, T.; Alcazar-Fuoli, L.; Mellado, E. Point Mutations in the 14-α Sterol Demethylase Cyp51A or Cyp51C Could Contribute to Azole Resistance in Aspergillus Flavus. Genes 2020, 11, 1217. [Google Scholar] [CrossRef]
- Paul, R.A.; Rudramurthy, S.M.; Meis, J.F.; Mouton, J.W.; Chakrabarti, A. A Novel Y319H Substitution in CYP51C Associated with Azole Resistance in Aspergillus Flavus. Antimicrob. Agents Chemother. 2015, 59, 6615–6619. [Google Scholar] [CrossRef] [Green Version]
- Yang, J.; Zhang, Y. I-TASSER Server: New Development for Protein Structure and Function Predictions. Nucleic Acids Res. 2015, 43, W174–W181. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, C.; Freddolino, P.L.; Zhang, Y. COFACTOR: Improved Protein Function Prediction by Combining Structure, Sequence and Protein-Protein Interaction Information. Nucleic Acids Res. 2017, 45, W291–W299. [Google Scholar] [CrossRef] [PubMed]
- Guinea, J. Updated EUCAST Clinical Breakpoints against Aspergillus, Implications for the Clinical Microbiology Laboratory. J. Fungi Basel Switz. 2020, 6, 343. [Google Scholar] [CrossRef] [PubMed]
- Alastruey-Izquierdo, A.; Cuenca-Estrella, M.; Monzón, A.; Mellado, E.; Rodríguez-Tudela, J.L. Antifungal Susceptibility Profile of Clinical Fusarium Spp. Isolates Identified by Molecular Methods. J. Antimicrob. Chemother. 2008, 61, 805–809. [Google Scholar] [CrossRef] [Green Version]
- Lalitha, P.; Shapiro, B.L.; Srinivasan, M.; Prajna, N.V.; Acharya, N.R.; Fothergill, A.W.; Ruiz, J.; Chidambaram, J.D.; Maxey, K.J.; Hong, K.C.; et al. Antimicrobial Susceptibility of Fusarium, Aspergillus, and Other Filamentous Fungi Isolated from Keratitis. Arch. Ophthalmol. 2007, 125, 789–793. [Google Scholar] [CrossRef]
- Cornely, O.A.; Mullane, K.M.; Ostrosky-Zeichner, L.; Maher, R.M.; Croos-Dabrera, R.; Lu, Q.; Lademacher, C.; Perfect, J.R.; Oren, I.; Schmitt-Hoffmann, A.-H.; et al. Isavuconazole for Treatment of Rare Invasive Fungal Diseases. Mycoses 2018, 61, 518–533. [Google Scholar] [CrossRef] [Green Version]
- Broutin, A.; Bigot, J.; Senghor, Y.; Moreno-Sabater, A.; Guitard, J.; Hennequin, C. In Vitro Susceptibility of Fusarium to Isavuconazole. Antimicrob. Agents Chemother. 2020, 64, e01621-19. [Google Scholar] [CrossRef]
- Jørgensen, K.M.; Astvad, K.M.T.; Hare, R.K.; Arendrup, M.C. EUCAST Susceptibility Testing of Isavuconazole: MIC Data for Contemporary Clinical Mold and Yeast Isolates. Antimicrob. Agents Chemother. 2019, 63, e00073-19. [Google Scholar] [CrossRef] [Green Version]
- Mortensen, K.L.; Jensen, R.H.; Johansen, H.K.; Skov, M.; Pressler, T.; Howard, S.J.; Leatherbarrow, H.; Mellado, E.; Arendrup, M.C. Aspergillus Species and Other Molds in Respiratory Samples from Patients with Cystic Fibrosis: A Laboratory-Based Study with Focus on Aspergillus Fumigatus Azole Resistance. J. Clin. Microbiol. 2011, 49, 2243–2251. [Google Scholar] [CrossRef] [Green Version]
- Alcazar-Fuoli, L.; Mellado, E.; Cuenca-Estrella, M.; Sanglard, D. Probing the Role of Point Mutations in the Cyp51A Gene from Aspergillus Fumigatus in the Model Yeast Saccharomyces Cerevisiae. Med. Mycol. 2011, 49, 276–284. [Google Scholar] [CrossRef] [Green Version]
- Snelders, E.; Karawajczyk, A.; Schaftenaar, G.; Verweij, P.E.; Melchers, W.J.G. Azole Resistance Profile of Amino Acid Changes in Aspergillus Fumigatus CYP51A Based on Protein Homology Modeling. Antimicrob. Agents Chemother. 2010, 54, 2425–2430. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gonzalez-Jimenez, I.; Lucio, J.; Amich, J.; Cuesta, I.; Sanchez Arroyo, R.; Alcazar-Fuoli, L.; Mellado, E. A Cyp51B Mutation Contributes to Azole Resistance in Aspergillus Fumigatus. J. Fungi Basel Switz. 2020, 6, 315. [Google Scholar] [CrossRef] [PubMed]
- Da Silva Ferreira, M.E.; Capellaro, J.L.; dos Reis Marques, E.; Malavazi, I.; Perlin, D.; Park, S.; Anderson, J.B.; Colombo, A.L.; Arthington-Skaggs, B.A.; Goldman, M.H.S.; et al. In Vitro Evolution of Itraconazole Resistance in Aspergillus Fumigatus Involves Multiple Mechanisms of Resistance. Antimicrob. Agents Chemother. 2004, 48, 4405–4413. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liu, X.; Yu, F.; Schnabel, G.; Wu, J.; Wang, Z.; Ma, Z. Paralogous Cyp51 Genes in Fusarium Graminearum Mediate Differential Sensitivity to Sterol Demethylation Inhibitors. Fungal Genet. Biol. 2011, 48, 113–123. [Google Scholar] [CrossRef] [PubMed]
- Fan, J.; Urban, M.; Parker, J.E.; Brewer, H.C.; Kelly, S.L.; Hammond-Kosack, K.E.; Fraaije, B.A.; Liu, X.; Cools, H.J. Characterization of the Sterol 14α-Demethylases of Fusarium Graminearum Identifies a Novel Genus-Specific CYP51 Function. New Phytol. 2013, 198, 821–835. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Van Rhijn, N.; Bromley, M.; Richardson, M.; Bowyer, P. CYP51 Paralogue Structure Is Associated with Intrinsic Azole Resistance in Fungi. MBio 2021, 12, e01945-21. [Google Scholar] [CrossRef]
- Zheng, B.; Yan, L.; Liang, W.; Yang, Q. Paralogous Cyp51s Mediate the Differential Sensitivity of Fusarium Oxysporum to Sterol Demethylation Inhibitors. Pest Manag. Sci. 2019, 75, 396–404. [Google Scholar] [CrossRef]
- Fan, J.; Chen, F.; Diao, Y.; Cools, H.J.; Kelly, S.L.; Liu, X. The Y123H Substitution Perturbs FvCYP51B Function and Confers Prochloraz Resistance in Laboratory Mutants of Fusarium verticillioides. Plant Pathol. 2014, 63, 952–960. [Google Scholar] [CrossRef] [Green Version]
- Zhao, B.; He, D.; Wang, L. Advances in Fusarium Drug Resistance Research. J. Glob. Antimicrob. Resist. 2021, 24, 215–219. [Google Scholar] [CrossRef]
Figure 1.
Calculated model of FSSC CYP51A protein. Point mutations shared by all FSSC strains and known to be associated with azole resistance in A. fumigatus are indicated by the amino acid letter and position. Amino acid L218 interacts with F75, and both are present at the entry of the substrate channel (yellow: heme; blue: itraconazole; purple: F75; red: L218, corresponding to the channel entry for the substrate).
Figure 1.
Calculated model of FSSC CYP51A protein. Point mutations shared by all FSSC strains and known to be associated with azole resistance in A. fumigatus are indicated by the amino acid letter and position. Amino acid L218 interacts with F75, and both are present at the entry of the substrate channel (yellow: heme; blue: itraconazole; purple: F75; red: L218, corresponding to the channel entry for the substrate).
Table 1.
Characteristics of the Fusarium solani species complex strains used in this study.
| Study Number | Collection Number | Genotype | Origin | ||
|---|---|---|---|---|---|
| Location | Geography | Year of Isolation | |||
| FSSC20 | CBS 124901 | 2-w | Skin | France | 2008 |
| FSSC21 | CBS 124631 | 1-b | Nail | France | 2008 |
| FSCC25 | CBS 124895 | 5-o | Skin | France | 2008 |
| FSSC29 | CBS 124889 | 2-d | Nail | France | 2008 |
| FSSC36 | CBS 124890 | 5-v | Nail | France | 2008 |
| FSSC45 | CBS 124898 | 2-d | Skin | Gabon | 2008 |
| FSSC47 | CBS 124892 | 20-f | Nail | Gabon | 2008 |
| FSSC86 | CBS 102824 | 25-d | Plated litter fragment | Colombia | 2000 |
| FSSC90 | CBS 208.29 | 25-d | Hyacinthus orientalis | Germany | no data |
| FSSC98 | CBS 119996 | 5-kk | Daucus carota | Netherlands | no data |
| FSSC99 | CBS 119223 | 21-f | Carrot | Spain | no data |
| FSSC102 | CBS 115659 | 21-c | Potato cultivar Maritta | Germany | no data |
| FSSC111 | CBS 115660 | 21-d | Potato | Egypt | no data |
| FSSC112 | CBS 115658 | 21-e | Potato | Israel | no data |
| FSSC115 | CBS 109028 | 28-c | Subcutaneous nodule | Switzerland | no data |
| FSSC118 | CBS 224.34 | 1-b | Toe nail | Cuba | 1929 |
| FSSC121 | CBS 117608 | 6-f | Arm lesion human dermis | Turkey | no data |
Table 2.
Genes and mRNA accession numbers of Fusarium vanettenii mpVI 77-13-4 used in this study.
| Isoform | Gene | mRNA |
|---|---|---|
| CYP51A | NECHADRAFT_43488 (1583 bp) | XM_003045158.1 (1521 bp) |
| CYP51B | NECHADRAFT_57370 (1965 bp) | XM_003054190.1 (1802 bp) |
| CYP51C | NECHADRAFT_41888 (1649 bp) | XM_003051375.1 (1551 bp) |
Table 3.
Aspergillus sp. and Fusarium complex references and accession numbers of CYP51A, CYP51B, and CYP51C protein sequences used in our comparisons.
Table 3.
Aspergillus sp. and Fusarium complex references and accession numbers of CYP51A, CYP51B, and CYP51C protein sequences used in our comparisons.
| Protein | Complex | Denomination | Accession Number |
|---|---|---|---|
| CYP51A | / | Aspergillus fumigatus NRRL:163 | AAK73659 |
| Fusarium solani complex | Fusarium falciforme | QGZ00344.1 | |
| Fusarium floridanum | RSL78044.1 | ||
| Fusarium keratoplasticum | QGR26268.1 | ||
| Fusarium suttonianum | QGZ00346.1 | ||
| Fusarium oxysporum complex | Fusarium odoratissimum NRRL 54006 | XP_031067647.1 | |
| Fusarium oxysporum f. sp. lycopersicum 4287 | XP_018249823.1 | ||
| Fusarium fujikuroi complex | Fusarium denticulatum | KAF5688222.1 | |
| Fusarium fujikuroi IMI 58289 | XP_023435732.1 | ||
| Fusarium proliferatum ET1 | XP_031088172.1 | ||
| Fusarium verticillioides 7600 | XP_018757407 | ||
| Fusarium sambucinum complex | Fusarium graminearum PH-1 | XP_011321548.1 | |
| Fusarium pseudograminearum CS3096 | XP_009251504.1 | ||
| CYP51B | / | Aspergillus fumigatus NRRL:163 | AAK73660 |
| CYP51C | / | Aspergillus flavus NRRL3357 | QRD94494 |
Table 4.
Antifungal susceptibility results of FSSC strains: MIC median and ranges.
| Antifungal | MIC (µg/mL) | |
|---|---|---|
| Median | Range | |
| Voriconazole | 8 | 2–16 |
| Itraconazole | >16 | / |
| Posaconazole | >16 | / |
| Isavuconazole | 16 | 4–64 |
Table 5.
Minimum inhibitory concentrations (MICs) of the FSSC strains for azole antifungals (voriconazole (VRZ), itraconazole (ITZ), posaconazole (PSZ), isavuconazole (IVZ)) and corresponding homology profiles of CYP51A, B, and C for each FSSC strain (n/a: data unavailable). Studied strains are classified in ascending order of voriconazole MICs. MICs for other tested azoles are also shown. Each protein sequence of CYP51A, B, and C was compared between the different FSSC strains and observed homologies were used to define profiles. Two strains share the same profile when their protein sequences present more than 99% of similarity. Profiles are noted with a number and a letter corresponding to the isoform. Numbers were chosen arbitrarily based on the order of strains with respect to voriconazole MIC. For each CYP51 isoform, the color gradient corresponds to the proximity of the protein profiles to each other (from green to red).
Table 5.
Minimum inhibitory concentrations (MICs) of the FSSC strains for azole antifungals (voriconazole (VRZ), itraconazole (ITZ), posaconazole (PSZ), isavuconazole (IVZ)) and corresponding homology profiles of CYP51A, B, and C for each FSSC strain (n/a: data unavailable). Studied strains are classified in ascending order of voriconazole MICs. MICs for other tested azoles are also shown. Each protein sequence of CYP51A, B, and C was compared between the different FSSC strains and observed homologies were used to define profiles. Two strains share the same profile when their protein sequences present more than 99% of similarity. Profiles are noted with a number and a letter corresponding to the isoform. Numbers were chosen arbitrarily based on the order of strains with respect to voriconazole MIC. For each CYP51 isoform, the color gradient corresponds to the proximity of the protein profiles to each other (from green to red).
| Strains | Antifungal MICs (µg/mL) | Profiles | |||||
|---|---|---|---|---|---|---|---|
| VRZ | ITZ | PSZ | IVZ | CYP51A | CYP51B | CYP51C | |
| FSSC20 | 2 | >16 | 8 | 16 | 3a | 2b | 2c |
| FSSC102 | 2 | >16 | >16 | 8 | 1a | 1b | n/a |
| FSSC111 | 2 | >16 | >16 | 4 | 1a | 1b | 1c |
| FSSC112 | 2 | >16 | >16 | 4 | 1a | n/a | 1c |
| FSSC45 | 4 | >16 | >16 | 16 | 2a | 2b | 2c |
| FSSC98 | 4 | >16 | >16 | 16 | 4a | 3b | 3c |
| FSSC99 | 4 | >16 | >16 | 8 | 1a | 1b | 1c |
| FSSC115 | 4 | >16 | >16 | 4 | 7a | 4b | 5c |
| FSSC21 | 8 | >16 | >16 | 16 | 5a | 4b | n/a |
| FSSC25 | 8 | >16 | >16 | 16 | 8a | 4b | 4c |
| FSSC29 | 8 | >16 | >16 | 16 | 2a | 4b | 2c |
| FSSC36 | 8 | >16 | >16 | 32 | 4a | 3b | 3c |
| FSSC86 | 8 | >16 | >16 | 16 | 6a | 4b | 4c |
| FSSC90 | 8 | >16 | >16 | 8 | 4a | 3b | n/a |
| FSSC118 | 8 | >16 | >16 | 16 | 5a | 4b | 4c |
| FSSC121 | 8 | >16 | >16 | 16 | 8a | 4b | 4c |
| FSSC47 | 16 | >16 | >16 | 64 | 9a | 3b | 3c |
Table 6.
Comparison of amino acid changes observed in our FSSC strains with those associated with azole resistance in A. fumigatus CYP51A (green: point mutations different from wild-type (WT) and mutated (azole R) A. fumigatus; orange: point mutation different from WT A. fumigatus but identical to resistant A. fumigatus (azole R)).
Table 6.
Comparison of amino acid changes observed in our FSSC strains with those associated with azole resistance in A. fumigatus CYP51A (green: point mutations different from wild-type (WT) and mutated (azole R) A. fumigatus; orange: point mutation different from WT A. fumigatus but identical to resistant A. fumigatus (azole R)).
| Aspergillus fumigatus | Fusarium solani Species Complex | ||||
|---|---|---|---|---|---|
| Position | Amino Acid | Position | Amino Acid | Strains | |
| WT | Azole R | ||||
| 22 | N | D | 22 | H | All |
| 46 | F | Y | 46 | F | All |
| 52 | S | T | 52 | S | All |
| 54 | G | E, K, R, V, W | 54 | G | All |
| 98 | L | H | 98 | L | All |
| 121 | Y | F | 121 | Y | All |
| 138 | G | C, R | 138 | G | All |
| 141 | Q | H | 141 | Q | All |
| 147 | H | Y | 147 | H | All |
| 172 | M | V | 170 | V | All |
| 216 | P | L | 214 | P | All |
| 220 | M | K, I, T, V | 218 | L | All |
| 248 | N | T | 246 | N | All |
| 255 | D | E | 253 | G | All |
| 289 | T | A | 287 | T | All |
| 297 | S | T | 295 | S | All |
| 394 | P | L | 389 | P | All |
| 427 | E | G, K | 422 | D | All |
| 431 | Y | C | 426 | Y | All |
| 434 | G | C | 429 | G | All |
| 440 | T | A | 435 | T | All |
| 448 | G | S | 443 | G | All |
| 491 | Y | H | 486 | Y | All |
| 495 | F | I | 490 | F | All |
Table 7.
Mutations of interest observed in FSSC strains, corresponding amino acids, physicochemical properties, and their impact on azole resistance (A: apolar; P: polar uncharged, −: negative polar; +: positive polar; ATU: area of technical uncertainty, R: resistant, n/a: data unavailable).
Table 7.
Mutations of interest observed in FSSC strains, corresponding amino acids, physicochemical properties, and their impact on azole resistance (A: apolar; P: polar uncharged, −: negative polar; +: positive polar; ATU: area of technical uncertainty, R: resistant, n/a: data unavailable).
| Aspergillus fumigatus | Fusarium solani Species Complex | ||||||
|---|---|---|---|---|---|---|---|
| Position | WT | Mutant | Azole Resistance [23,34] | Position | Amino Acid | ||
| VRZ | ITZ | PSZ | |||||
| 22 | Asn (P) | Asp (−) | n/a | R | n/a | 22 | His (+) |
| 172 | Met (A) | Val (A) | R | R | V | 170 | Val (A) |
| 220 | Met (A) | Lys (+) | ATU/R | R | R | 218 | Leu (A) |
| Ile/Va (A) | |||||||
| Thr (P) | |||||||
| 255 | Asp (−) | Glu (−) | R | R | ATU | 253 | Gly (A) |
| 427 | Glu (−) | Gly (A) | R | R | V | 422 | Asp (−) |
| Lys (+) | |||||||
Table 8.
Comparison of the five mutations of interest in CYP51A between studied strains and other strains from different species complexes (FSSC, FOSC, FFSC, FSAMSC) (D: aspartic acid; E: glutamic acid; G: glycine; H: histidine; I: isoleucine; L: leucine; N: asparagine; V: valine).
Table 8.
Comparison of the five mutations of interest in CYP51A between studied strains and other strains from different species complexes (FSSC, FOSC, FFSC, FSAMSC) (D: aspartic acid; E: glutamic acid; G: glycine; H: histidine; I: isoleucine; L: leucine; N: asparagine; V: valine).
| Complexes | Position | ||||
|---|---|---|---|---|---|
| 22 | 170 | 218 | 253 | 422 | |
| Fusarium solani species complex (FSSC) | |||||
| Strains from this study | H | V | L | G | D |
| Fusarium falciforme | H | V | L | G | D |
| Fusarium floridanum | H | V | L | G | D |
| Fusarium keratoplasticum | H | V | L | G | D |
| Fusarium suttonianum | H | V | L | G | D |
| Fusarium oxysporum species complex (FOSC) | |||||
| Fusarium odoratissimum NRRL 54006 | N | V | L | G | D |
| Fusarium oxysporum f. sp. lycopersicum 4287 | N | V | L | G | D |
| Fusarium fujikuroi species complex (FFSC) | |||||
| Fusarium denticulatum | N | V | L | G | E |
| Fusarium fujikuroi IMI 58289 | N | V | L | G | E |
| Fusarium proliferatum ET1 | N | V | L | G | E |
| Fusarium verticillioides 7600 | N | V | L | G | E |
| Fusarium sambucinum species complex (FSAMSC) | |||||
| Fusarium graminearum PH-1 | N | I | L | I | D |
| Fusarium pseudograminearum CS3096 | N | I | L | I | D |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Vermeulen, P.; Gruez, A.; Babin, A.-L.; Frippiat, J.-P.; Machouart, M.; Debourgogne, A. CYP51 Mutations in the Fusarium solani Species Complex: First Clue to Understand the Low Susceptibility to Azoles of the Genus Fusarium. J. Fungi 2022, 8, 533. https://doi.org/10.3390/jof8050533
AMA Style
Vermeulen P, Gruez A, Babin A-L, Frippiat J-P, Machouart M, Debourgogne A. CYP51 Mutations in the Fusarium solani Species Complex: First Clue to Understand the Low Susceptibility to Azoles of the Genus Fusarium. Journal of Fungi. 2022; 8(5):533. https://doi.org/10.3390/jof8050533
Chicago/Turabian StyleVermeulen, Pierre, Arnaud Gruez, Anne-Lyse Babin, Jean-Pol Frippiat, Marie Machouart, and Anne Debourgogne. 2022. "CYP51 Mutations in the Fusarium solani Species Complex: First Clue to Understand the Low Susceptibility to Azoles of the Genus Fusarium" Journal of Fungi 8, no. 5: 533. https://doi.org/10.3390/jof8050533
APA StyleVermeulen, P., Gruez, A., Babin, A. -L., Frippiat, J. -P., Machouart, M., & Debourgogne, A. (2022). CYP51 Mutations in the Fusarium solani Species Complex: First Clue to Understand the Low Susceptibility to Azoles of the Genus Fusarium. Journal of Fungi, 8(5), 533. https://doi.org/10.3390/jof8050533
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
